Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7

Gerotziafas, Grigoris T.; Galea, Vassiliki; Mbemba, Elisabeth; Khaterchi, Amir; Sassi, Mouna; Baccouche, Hela; Prengel, Claudie; Dreden, Patrick Van; Hatmi, Mohamed; Bernaudin, J.-F.; Elalamy, Ismaı̈l

doi:10.1016/j.thromres.2011.07.049

Cited by 39 publications

(43 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously described [52], cells were suspended in PBS at a concentration of 1.2×10 7 cells/ml and incubated with mouse anti-TF antibody (ADG4508, Sekisui, MA) 1:25 or isotype mouse IgG antibody (AB18447, Abcam, SF) 1:50 for 20 minutes at RT. After PBS washes, cells were incubated for 20 minutes with APC-linked goat anti-mouse-IgG antibody (A865, Invitrogen) at RT before resuspending in PBS.…”

Section: Methodsmentioning

confidence: 99%

Tissue Factor promotes breast cancer stem cell activity in vitro

et al. 2016

View full text Add to dashboard Cite

Cancer stem cells (CSCs) are a subpopulation of cells that can self-renew and initiate tumours. The clotting-initiating protein Tissue Factor (TF) promotes metastasis and may be overexpressed in cancer cells with increased CSC activity. We sought to determine whether TF promotes breast CSC activity in vitro using human breast cancer cell lines. TF expression was compared in anoikis-resistant (CSC-enriched) and unselected cells. In cells sorted into of TF-expressing and TF-negative (FACS), and in cells transfected to knockdown TF (siRNA) and overexpress TF (cDNA), CSC activity was compared by (i) mammosphere forming efficiency (MFE) (ii) holoclone colony formation (Hc) and (iii) ALDH1 activity. TF expression was increased in anoikis-resistant and high ALDH1-activity T47D cells compared to unselected cells. FACS sorted TF-expressing T47Ds and TF-overexpressing MCF7s had increased CSC activity compared to TF-low cells. TF siRNA cells (MDAMB231, T47D) had reduced CSC activity compared to control cells. FVIIa increased MFE and ALDH1 in a dose-dependent manner (MDAMB231, T47D). The effects of FVIIa on MFE were abrogated by TF siRNA (T47D). Breast CSCs (in vitro) demonstrate increased activity when selected for high TF expression, when induced to overexpress TF, and when stimulated (with FVIIa). Targeting the TF pathway in vivo may abrogate CSC activity.

show abstract

Section: Methodsmentioning

confidence: 99%

Tissue Factor promotes breast cancer stem cell activity in vitro

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Similarly, platelets were recently shown to be capable of inducing EMT in cancer[21,22]. Pancreatic cancer is associated with a high risk of venous thromboembolism (VTE) caused by tumour-derived or tumour-elicited tissue factor which can indirectly induce platelets aggregation[23,24]. Whether targeting platelets can offer an indirect way to reduce EMT and chemoresistance as well as the risk of VTE in pancreatic cancer is yet to be demonstrated.…”

Section: General Considerations On Pharmacological Approaches To Targmentioning

confidence: 99%

Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer

Elaskalani¹,

Razak²,

Falasca³

et al. 2017

WJGO

View full text Add to dashboard Cite

Pancreatic cancer has one of the worst prognoses among all cancers due to the late manifestation of identifiable symptoms and high resistance to chemo- and radiation therapies. In recent years, a cancer development phase termed epithelial-mesenchymal transition (EMT) has gained increasing research focus. The process is implicated in tumour metastasis, and emerging evidence suggests EMT also contributes or induces chemoresistance in several cancers. Nevertheless, the applicability of therapeutic targeting of EMT faces many challenges. In this mini-review, we summarise the evidence supporting the role of EMT in pancreatic cancer progression, focusing particularly on its association with chemoresistance.

show abstract

“…This binding leads to the proteolytic activation of various coagulation zymogens, such as FX, FIX and prothrombin, resulting in the formation of a fibrin clot. Interestingly, TF expression is up-regulated on the surface of transformed cells, which has long been implicated in the in vitro procoagulant activity and cell aggressiveness of different tumour cell lines [16–18]. Moreover, TF was shown to be overexpressed in samples from patients with various neoplasias, including most carcinomas and other tumours such as melanoma [19].…”

Section: Extravascular Activation Of Blood Coagulation In Cancermentioning

confidence: 99%

Activation of blood coagulation in cancer: implications for tumour progression

2013

View full text Add to dashboard Cite

Several studies have suggested a role for blood coagulation proteins in tumour progression. Herein, we discuss (1) the activation of the blood clotting cascade in the tumour microenvironment and its impact on primary tumour growth; (2) the intravascular activation of blood coagulation and its impact on tumour metastasis and cancer-associated thrombosis; and (3) antitumour therapies that target blood-coagulation-associated proteins. Expression levels of the clotting initiator protein TF (tissue factor) have been correlated with tumour cell aggressiveness. Simultaneous TF expression and PS (phosphatidylserine) exposure by tumour cells promote the extravascular activation of blood coagulation. The generation of blood coagulation enzymes in the tumour microenvironment may trigger the activation of PARs (protease-activated receptors). In particular, PAR1 and PAR2 have been associated with many aspects of tumour biology. The procoagulant activity of circulating tumour cells favours metastasis, whereas the release of TF-bearing MVs (microvesicles) into the circulation has been correlated with cancer-associated thrombosis. Given the role of coagulation proteins in tumour progression, it has been proposed that they could be targets for the development of new antitumour therapies.

show abstract

Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7

Cited by 39 publications

References 39 publications

Tissue Factor promotes breast cancer stem cell activity in vitro

Tissue Factor promotes breast cancer stem cell activity in vitro

Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer

Activation of blood coagulation in cancer: implications for tumour progression

Contact Info

Product

Resources

About